Inventor
WUSTROW DAVID J
US25 patents
⚠️ This page may combine multiple inventors who share the name “WUSTROW DAVID J”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
WARNER LAMBERT CO
11 patentsUS5407916AApr 18, 1995
Neurotensin mimetics as central nervous system agents
WARNER LAMBERT CO20 citations92
US6177422B1Jan 23, 2001
Benzoxazinone dopamine D4 receptor antagonists
WARNER LAMBERT CO10 citations73
US5430047AJul 4, 1995
Neurotensin antagonists
WARNER LAMBERT CO9 citations72
US5409931AApr 25, 1995
1,3-substituted cycloalkenes and cycloalkanes as central nervous system agents
WARNER LAMBERT CO7 citations72
US5314896AMay 24, 1994
1,3-substituted cycloalkenes and cycloalkanes as central nervous system agents
WARNER LAMBERT CO9 citations72
US5187280AFeb 16, 1993
Substituted tetrahydropyridines and their use as central nervous system agents
WARNER LAMBERT CO7 citations72
US5118691AJun 2, 1992
Substituted tetrahydropyridines as central nervous system agents
WARNER LAMBERT CO13 citations72
US5089497AFeb 18, 1992
Substituted piperazines as central nervous system agents
WARNER LAMBERT CO14 citations72
US5045550ASep 3, 1991
Substituted tetrahydropyridines as central nervous system agents
WARNER LAMBERT CO11 citations72
US5977110ANov 2, 1999
Substituted cyclohexylamines as central nervous systems agents
WARNER LAMBERT CO2 citations60
US5206233AApr 27, 1993
Substituted thiazepines as central nervous system agents
WARNER LAMBERT CO2 citations60
XENOPORT INC
5 patentsUS8344028B2Jan 1, 2013
Gamma-amino-butyric acid derivatives as GABAB receptor ligands
XENOPORT INC43 citations93
US8952006B2Feb 10, 2015
Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use
XENOPORT INC15 citations84
US10716760B2Jul 21, 2020
Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
XENOPORT INC2 citations69
US9597292B2Mar 21, 2017
Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
XENOPORT INC0 citations48
US8377956B2Feb 19, 2013
Use of (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl) butanoic acid for treating urinary incontinence
XENOPORT INC1 citations42
RAPT THERAPEUTICS INC
5 patentsUS11046699B2Jun 29, 2021
Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
RAPT THERAPEUTICS INC3 citations65
US12428393B2Sep 30, 2025
Methods of making trans isomeric forms of G protein-coupled receptor modulators
RAPT THERAPEUTICS INC1 citations58
US12006318B2Jun 11, 2024
Crystalline forms of C-C chemokine receptor type 4 antagonist and uses thereof
RAPT THERAPEUTICS INC0 citations58
US12240837B2Mar 4, 2025
Chemokine receptor modulators and uses thereof
RAPT THERAPEUTICS INC0 citations50
US11918582B2Mar 5, 2024
Pyrazole pyrimidine compounds and uses thereof
RAPT THERAPEUTICS INC0 citations42